These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1359 related items for PubMed ID: 18178602

  • 1. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N.
    Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
    [Abstract] [Full Text] [Related]

  • 2. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z, Krejcí M, Pour L, Stepánková S, Cermáková Z, Voska L, Teplan V, Krivanová A, Hájek R, Mayer J.
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [Abstract] [Full Text] [Related]

  • 3. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, Olavarria E, Goldman JM, Rahemtulla A.
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [Abstract] [Full Text] [Related]

  • 4. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [Abstract] [Full Text] [Related]

  • 5. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH, Korean Multiple Myeloma Working Party.
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [Abstract] [Full Text] [Related]

  • 6. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
    Alegre A, Granda A, Martínez-Chamorro C, Díaz-Mediavilla J, Martínez R, García-Laraña J, Lahuerta JJ, Sureda A, Bladé J, de la Rubia J, Fernández-Rañada JM, San Miguel J, Spanish Registry of Transplants in Multiple Myelomas, Spanish Group of Hemopoietic Transplant (GETH), PETHEMA.
    Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
    [Abstract] [Full Text] [Related]

  • 7. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V.
    Natl Med J India; 2003 Jun; 16(1):16-21. PubMed ID: 12715951
    [Abstract] [Full Text] [Related]

  • 8. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT, Waller EK, Leong T, Heffner LT, Redei I, Langston AA, Lonial S.
    Cancer; 2006 May 15; 106(10):2171-80. PubMed ID: 16598756
    [Abstract] [Full Text] [Related]

  • 9. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P, Gisslinger H, Raderer M, Geissler K, Höcker P, Zielinski CC, Oberbauer R, Greinix HT.
    Wien Klin Wochenschr; 2006 Feb 15; 118(1-2):49-53. PubMed ID: 16489526
    [Abstract] [Full Text] [Related]

  • 10. Biopsy-proven resolution of renal light-chain deposition disease after autologous stem cell transplantation.
    Petrakis I, Stylianou K, Mavroeidi V, Vardaki E, Stratigis S, Stratakis S, Xylouri I, Perakis C, Petraki C, Nakopoulou L, Daphnis E.
    Nephrol Dial Transplant; 2010 Jun 15; 25(6):2020-3. PubMed ID: 20133281
    [Abstract] [Full Text] [Related]

  • 11. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
    Ganguly S, Divine CL, Deauna-Limayo D, Bodensteiner DC, Cook JD, Lewis JN, Skikne BS.
    Ann Hematol; 2005 Aug 15; 84(8):526-31. PubMed ID: 15915350
    [Abstract] [Full Text] [Related]

  • 12. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.
    Br J Haematol; 2004 Dec 15; 127(5):543-51. PubMed ID: 15566357
    [Abstract] [Full Text] [Related]

  • 13. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
    Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Wendt R, Breitz H, Alexanian R, Champlin R, Giralt S.
    Biol Blood Marrow Transplant; 2007 May 15; 13(5):543-9. PubMed ID: 17448913
    [Abstract] [Full Text] [Related]

  • 14. Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Garderet L, Gras L, Koster L, De Wreede L, Montserrat R, Vincent L, Fenk R, Karunanithi K, Deeren D, Kaufmann M, Kuball J, Ozdogu H, Cascon MJP, Passweg J, Rye A, Salmenniemi U, Snowden J, Hansen CT, Leleu X, Gastaud L, Sokolowska JD, Raj K, Beksac M, Schönland S, Hayden P, McLornan D.
    Haematologica; 2024 Aug 01; 109(8):2619-2627. PubMed ID: 38546696
    [Abstract] [Full Text] [Related]

  • 15. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
    Kumar SK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA.
    Bone Marrow Transplant; 2008 Jun 01; 41(12):1013-9. PubMed ID: 18332915
    [Abstract] [Full Text] [Related]

  • 16. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP.
    Biol Blood Marrow Transplant; 2008 Jan 01; 14(1):116-24. PubMed ID: 18158968
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
    Eom KS, Min CK, Lee S, Kim YJ, Kim SY, Kim HJ, Lee JW, Min WS, Kim CC.
    Jpn J Clin Oncol; 2006 Jul 01; 36(7):432-8. PubMed ID: 16782727
    [Abstract] [Full Text] [Related]

  • 18. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.
    Ruiz-Soto R, Sergent G, Gisselbrecht C, Larghero J, Ertault M, Hennequin C, Manson J, de Kerviler E, Briere J, Mounier N.
    Cancer; 2005 Dec 15; 104(12):2735-42. PubMed ID: 16284986
    [Abstract] [Full Text] [Related]

  • 19. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE.
    Haematologica; 2005 Dec 15; 90(12):1650-4. PubMed ID: 16330438
    [Abstract] [Full Text] [Related]

  • 20. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N, Dispenzieri A, Fervenza FC, Lacy MQ, Villicana R, Cavalcante JL, Gertz MA.
    Am J Kidney Dis; 2005 Aug 15; 46(2):270-7. PubMed ID: 16112045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.